Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile. (Q36062034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

review article

1 reference

title

Amprenavir or fosamprenavir plus ritonavir in HIV infection: pharmacology, efficacy and tolerability profile (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Olivier Tribut

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

language of work or name

1 reference

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

65

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

633-659

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:15748098%20AND%20SRC:MED&resulttype=core&format=json

Prospective, intensive study of metabolic changes associated with 48 weeks of amprenavir-based antiretroviral therapy

9 January 2020

cites work

1 reference

12 December 2020

In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats

1 reference

12 December 2020

Pharmacokinetic interaction between lopinavir/r and amprenavir in salvage therapy

1 reference

12 December 2020

Amprenavir: a new human immunodeficiency virus type 1 protease inhibitor

1 reference

12 December 2020

Clinical pharmacology and pharmacokinetics of amprenavir.

1 reference

12 December 2020

Twice-daily amprenavir 1200 mg versus amprenavir 600 mg/ritonavir 100 mg, in combination with at least 2 other antiretroviral drugs, in HIV-1-infected patients

1 reference

12 December 2020

Unfavourable interaction of amprenavir and lopinavir in combination with ritonavir?

1 reference

12 December 2020

Pharmacokinetics of amprenavir and lopinavir in combination with nevirapine in highly pretreated HIV-infected patients

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing

1 reference

12 December 2020

Six-week randomized controlled trial to compare the tolerabilities, pharmacokinetics, and antiviral activities of GW433908 and amprenavir in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Pharmacokinetics and safety of amprenavir and ritonavir following multiple-dose, co-administration to healthy volunteers

1 reference

12 December 2020

Emergence of resistance to protease inhibitor amprenavir in human immunodeficiency virus type 1-infected patients: selection of four alternative viral protease genotypes and influence of viral susceptibility to coadministered reverse transcriptase n

1 reference

12 December 2020

Amprenavir: a review of its clinical potential in patients with HIV infection

1 reference

12 December 2020

Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients

1 reference

12 December 2020

Analysis of HIV cross-resistance to protease inhibitors using a rapid single-cycle recombinant virus assay for patients failing on combination therapies

1 reference

12 December 2020

Treatment with amprenavir alone or amprenavir with zidovudine and lamivudine in adults with human immunodeficiency virus infection. AIDS Clinical Trials Group 347 Study Team.

1 reference

12 December 2020

A review of low-dose ritonavir in protease inhibitor combination therapy

1 reference

12 December 2020

HIV-1 genotype and phenotype correlate with virological response to abacavir, amprenavir and efavirenz in treatment-experienced patients

1 reference

12 December 2020

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

12 December 2020

Efficacy of an educational and counseling intervention on adherence to highly active antiretroviral therapy: French prospective controlled study

1 reference

12 December 2020

Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: A positive drug-drug interaction

1 reference

12 December 2020

High variability of plasma drug concentrations in dual protease inhibitor regimens

1 reference

12 December 2020

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity

1 reference

12 December 2020

The effect of increasing alpha1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors

1 reference

12 December 2020

Efavirenz-induced decrease in plasma amprenavir levels in human immunodeficiency virus-infected patients and correction by ritonavir

1 reference

12 December 2020

A phase II safety and efficacy study of amprenavir in combination with zidovudine and lamivudine in HIV-infected patients with limited antiretroviral experience. Amprenavir PROAB2002 Study Team.

1 reference

12 December 2020

Salvage therapy with amprenavir and ritonavir: prospective study in 17 heavily pretreated patients.

1 reference

12 December 2020

GW433908/ritonavir once daily in antiretroviral therapy-naive HIV-infected patients: absence of protease resistance at 48 weeks

1 reference

12 December 2020

Amprenavir inhibitory quotient and virological response in human immunodeficiency virus-infected patients on an amprenavir-containing salvage regimen without or with ritonavir

1 reference

12 December 2020

The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients

1 reference

12 December 2020

Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity

1 reference

12 December 2020

Pharmacokinetics and safety of GW433908 and ritonavir, with and without efavirenz, in healthy volunteers

1 reference

12 December 2020

Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy

1 reference

12 December 2020

Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society-USA Panel.

1 reference

12 December 2020

Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients

1 reference

12 December 2020

Preclinical pharmacology and pharmacokinetics of GW433908, a water-soluble prodrug of the human immunodeficiency virus protease inhibitor amprenavir

1 reference

12 December 2020

Prevalence of the HIV protease mutation N88S causing hypersensitivity to amprenavir

1 reference

12 December 2020

A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection

1 reference

12 December 2020

Amprenavir in combination with lamivudine and zidovudine versus lamivudine and zidovudine alone in HIV-1-infected antiretroviral-naive adults. Amprenavir PROAB3001 International Study Team.

1 reference

12 December 2020

Amprenavir: new preparation. Another HIV protease inhibitor: no proven advance

1 reference

12 December 2020

A phase II trial of dual protease inhibitor therapy: amprenavir in combination with indinavir, nelfinavir, or saquinavir

1 reference

12 December 2020

Low level of cross-resistance to amprenavir (141W94) in samples from patients pretreated with other protease inhibitors

1 reference

12 December 2020

In vivo effect of alpha(1)-acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor

1 reference

12 December 2020

Pharmacokinetic modeling and simulations of interaction of amprenavir and ritonavir

1 reference

12 December 2020

Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions

1 reference

12 December 2020

In vitro antiviral activity of 141W94 (VX-478) in combination with other antiretroviral agents

1 reference

12 December 2020

A mutation in human immunodeficiency virus type 1 protease, N88S, that causes in vitro hypersensitivity to amprenavir

1 reference

12 December 2020